J N Kochenderfer

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint A comparison and critical analysis of preclinical anticancer vaccination strategies
    J N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Exp Biol Med (Maywood) 232:1130-41. 2007
  2. doi request reprint Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
    James N Kochenderfer
    James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P T Somerville, Robert O Carpenter, Maryalice Stetler Stevenson, James C Yang, Q Phan, Marybeth S Hughes, Richard M Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F Li, Lien T Ngo, Debbie Ann N Nathan, Kathleen E Morton, Mary Ann Toomey, and Steven A Rosenberg, National Cancer Institute Clara C Chen, Clinical Center, National Institutes of Health NIH Sarah M Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ David E Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada and Michael L Wang, MD Anderson Cancer Center, Houston, TX
    J Clin Oncol 33:540-9. 2015
  3. doi request reprint Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 10:267-76. 2013
  4. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
  5. pmc Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:3875-86. 2010
  6. pmc Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 32:689-702. 2009
  7. pmc Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive CRC 3 3288 Bethesda, MD 20892, USA
    Clin Immunol 124:119-30. 2007
  8. pmc Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:450-60. 2007
  9. ncbi request reprint Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:8860-73. 2006
  10. pmc Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    James N Kochenderfer
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 116:4099-102. 2010

Detail Information

Publications14

  1. ncbi request reprint A comparison and critical analysis of preclinical anticancer vaccination strategies
    J N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Exp Biol Med (Maywood) 232:1130-41. 2007
    ..Identification of vaccine characteristics that are associated with antitumor efficacy may aid in the development of more effective anticancer vaccination strategies...
  2. doi request reprint Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
    James N Kochenderfer
    James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P T Somerville, Robert O Carpenter, Maryalice Stetler Stevenson, James C Yang, Q Phan, Marybeth S Hughes, Richard M Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F Li, Lien T Ngo, Debbie Ann N Nathan, Kathleen E Morton, Mary Ann Toomey, and Steven A Rosenberg, National Cancer Institute Clara C Chen, Clinical Center, National Institutes of Health NIH Sarah M Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ David E Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada and Michael L Wang, MD Anderson Cancer Center, Houston, TX
    J Clin Oncol 33:540-9. 2015
    ..T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies...
  3. doi request reprint Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 10:267-76. 2013
    ..Although anti-CD19 CAR T cells are at an early stage of development, the potent antigen-specific activity observed in patients suggests that infusions of anti-CD19 CAR T cells might become a standard therapy for some B-cell malignancies...
  4. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
    ....
  5. pmc Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:3875-86. 2010
    ..Our results demonstrated impressive antilymphoma activity and profound destruction of normal B cells caused by anti-CD19-CAR-transduced T cells in a clinically relevant murine model...
  6. pmc Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 32:689-702. 2009
    ....
  7. pmc Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive CRC 3 3288 Bethesda, MD 20892, USA
    Clin Immunol 124:119-30. 2007
    ..These findings suggest strategies to increase the size of CD8(+) T cell responses generated by CpG-containing peptide vaccines that could be tested in future clinical trials...
  8. pmc Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:450-60. 2007
    ..This is the first report to demonstrate that CD8(+) T-cell responses capable of executing antitumor immunity can be elicited by CpG-containing vaccines during HPE...
  9. ncbi request reprint Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:8860-73. 2006
    ..This is the first report of synergism between CpG ODN and IL-2. This synergism caused a striking increase in vaccine-elicited CD8+ T cells and led to epitope-specific antitumor immunity...
  10. pmc Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    James N Kochenderfer
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 116:4099-102. 2010
    ..Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326...
  11. pmc Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells
    Steven A Feldman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 22:107-15. 2011
    ..To date, this platform has generated five clinical-grade gammaretroviral vector products, four of which are now being used in adoptive cell therapy clinical trials for the treatment of a variety of solid cancers...
  12. ncbi request reprint Leukemia vaccines
    J N Kochenderfer
    Division of Medicine and Section of Transplant Immunology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 3:193-200. 2001
    ..Vaccination with genetically modified leukemia cells and the use of dendritic cells in various vaccination approaches are all promising avenues of study for development of effective leukemia vaccines...
  13. doi request reprint A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 183:5563-74. 2009
    ..More importantly, PBLs expressing this new version of the 4D5 CAR could not only efficiently lyse the autologous fresh tumor digests, but they could strongly suppress tumor growth in a xenogenic mouse model...
  14. ncbi request reprint Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
    James N Kochenderfer
    Section of Transplantation Immunology, Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:3639-45. 2002
    ..Our results demonstrate that predominant clonal T cells that appear to be antigen-driven persist in patients with MDS unresponsive to immunosuppression, but predominant clones regress in responders to immunosuppression...